GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (AMEX:OGEN) » Definitions » Forward Rate of Return (Yacktman) %

Oragenics (Oragenics) Forward Rate of Return (Yacktman) % : 0.00% (As of Mar. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Oragenics Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Oragenics's forward rate of return for was 0.00%.

The historical rank and industry rank for Oragenics's Forward Rate of Return (Yacktman) % or its related term are showing as below:

During the past 13 years, Oragenics's highest Forward Rate of Return was 20.00. The lowest was 19.95. And the median was 20.00.

OGEN's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 10.77
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Oragenics Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Oragenics's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oragenics Forward Rate of Return (Yacktman) % Chart

Oragenics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oragenics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oragenics's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, Oragenics's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oragenics's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oragenics's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Oragenics's Forward Rate of Return (Yacktman) % falls into.



Oragenics Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Oragenics's Forward Rate of Return of Mar. 2024 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/1.44+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oragenics  (AMEX:OGEN) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Oragenics Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Oragenics's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oragenics (Oragenics) Business Description

Industry
Traded in Other Exchanges
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL, USA, 33634
Oragenics Inc is engaged in research and the development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its product (NT-CoV2-1) is an intranasal vaccine candidate to prevent coronavirus disease ("COVID-19") from the SARS-CoV-2 virus and variants thereof. Its focus on developing vaccines and novel antibiotics It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus.
Executives
Fred Telling director 501 ELLIOTT AVE. W., SUITE 400, SEATTLE WA 98119
John P Gandolfo director 62 TERRACE ROAD, WAYNE NJ 07470
Cassidy Bruce A. Sr. director C/O LOOP MEDIA, 700 N CENTRAL AVENUE, SUITE 430, GLENDALE CA 91203
Janet Huffman officer: CFO, Secretary and Treasurer 5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232
Robert C Koski director, 10 percent owner 1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Michael O'keefe Sullivan officer: CFO, Secretary and Treasurer 3000 BAYPORT DRIVE, SUITE 685, TAMPA FL 33607
Joseph Hernandez 10 percent owner C/O MICROLIN BIO, INC., NEW YORK NY 10022
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Koski Family Lp 10 percent owner 1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Alan Joslyn director, officer: CEO and President 39 OLD RIDGEBURY ROAD, DANBURY CT 06810
Charles L Pope director 4902 EISENHOWER BOULEVARD, TAMPA FL 33634
Christine L Koski director, 10 percent owner 1500 WEST UNIVERSITY PARKWAY, SARASOTA FL 34243
Beverly Koski 10 percent owner
Thomas L Koski 10 percent owner

Oragenics (Oragenics) Headlines

From GuruFocus